Evidence of pathway‐specific basophil anergy induced by peanut oral immunotherapy in peanut‐allergic children
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: In W esternized countries, over 1% of the population is allergic to peanuts or tree nuts, which carries a risk of severe allergic reactions. Several studies support the efficacy of peanut oral immunotherapy (OIT) for reducing the clinical sensitivity of affected individuals; however, the mechanisms of this effect are still being characterized. One mechanism that may contribute is the suppression of effector cells, such as basophils. Basophil anergy has been characterized in vitro as a pathway‐specific hyporesponsiveness; however, this has not been demonstrated to occur in vivo. Objective: To evaluate the hypothesis that basophil anergy occurs in vivo due to chronic allergen exposure in the setting of a clinical oral immunotherapy trial. Methods: Samples of peripheral blood were obtained from subjects during a placebo‐controlled clinical trial of peanut OIT. Basophil reactivity to in vitro stimulation with peanut allergen and controls was assessed by the upregulation of activation markers, CD 63 and CD 203c, measured by flow cytometry. Results: The upregulation of CD 63 following stimulation of the IgE receptor, either specifically with peanut allergen or non‐specifically with anti‐IgE antibody, was strongly suppressed by active OIT. However, OIT did not significantly suppress this response in basophils stimulated by the distinct fMLP receptor pathway. In the subset of subjects with egg sensitization, active peanut OIT also suppressed CD 63 upregulation in response to stimulation with egg allergen. Allergen OIT also suppressed the upregulation of CD 203c including in response to stimulation with IL‐3 alone. Conclusion: Peanut OIT induces a hyporesponsive state in basophils that is consistent with pathway‐specific anergy previously described in vitro. This suggests the hypothesis that effector cell anergy could contribute to clinical desensitization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosing and Managing Common Food Allergies: A Systematic Review
Chafen, J. J. S., Newberry, S. J., Riedl, M. A., Bravata, D. M., Maglione, M., Suttorp, M. J., Sundaram, V., Paige, N. M., Towfigh, A., Hulley, B. J., et al. (2010) · JAMA · doi:10.1001/jama.2010.582 · Cited by 482
Monitoring human basophil activation via CD63 monoclonal antibody 435
Knol, E. F., Mul, F. P. J., Jansen, H., Calafat, J., & Roos, D. (1991) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(91)90094-5 · Cited by 421 · cited 3×
“Anaphylactic degranulation results in the translocation of lysosomalassociated membrane proteins (LAMPs), including CD63, from a predominantly intracellular location to the cell surface [19, 20] resulting in a predominantly bi-modal distribution of CD63 expression corresponding to cells that have undergone degranulati…”
Background
Cited by
Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
Vickery, B. P., Scurlock, A. M., Kulis, M., Steele, P. H., Kamilaris, J., Berglund, J. P., Burk, C., Hiegel, A., Carlisle, S., Christie, L., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.007 · Cited by 436
Self-citationThe clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease
Hoffmann, H. J., Santos, A. F., Mayorga, C., Nopp, A., Eberlein, B., Ferrer, M., Rouzaire, P., Ebo, D. G., Sabato, V., Sanz, M. L., et al. (2015) · Allergy · doi:10.1111/all.12698 · Cited by 403
Self-citationEarly oral immunotherapy in peanut-allergic preschool children is safe and highly effective
Vickery, B. P., Berglund, J. P., Burk, C. M., Fine, J. P., Kim, E. H., Kim, J. I., Keet, C. A., Kulis, M., Orgel, K. G., Guo, R., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.05.027 · Cited by 397
Self-citationEpicutaneous immunotherapy for the treatment of peanut allergy in children and young adults
Jones, S. M., Sicherer, S. H., Burks, A. W., Leung, D. Y. M., Lindblad, R. W., Dawson, P., Henning, A. K., Berin, M. C., Chiang, D., Vickery, B. P., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.08.017 · Cited by 314
Self-citationEAACI Molecular Allergology User's Guide 2.0
Dramburg, S., Hilger, C., Santos, A. F., de las Vecillas, L., Aalberse, R. C., Acevedo, N., Aglas, L., Altmann, F., Arruda, K. L., Asero, R., et al. (2023) · Pediatric Allergy and Immunology · doi:10.1111/pai.13854 · Cited by 298
Metadata
- Authors
- Thyagarajan, A., Jones, S. M., Calatroni, A., Pons, L., Kulis, M., Woo, C. S., Kamalakannan, M., Vickery, B. P., Scurlock, A. M., Wesley Burks, A., & Shreffler, W. G.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2012-07-16
- Volume
- 42
- Issue
- 8
- Pages
- 1197-1205
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2079909497
- Cited by
- 113
- References
- 2
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence of pathway‐specific basophil anergy induced by peanut oral immunotherapy in peanut‐allergic children. https://app.cochat.ai/papers/10.1111/j.1365-2222.2012.04028.x
- The paper
- Thyagarajan, A., Jones, S. M., Calatroni, A., Pons, L., Kulis, M., Woo, C. S., Kamalakannan, M., Vickery, B. P., Scurlock, A. M., Wesley Burks, A., & Shreffler, W. G. (2012). Evidence of pathway‐specific basophil anergy induced by peanut oral immunotherapy in peanut‐allergic children. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2012.04028.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.